GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX20) » Definitions » Beginning Cash Position

BioXcel Therapeutics (FRA:BX20) Beginning Cash Position : €27.62 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Beginning Cash Position?

BioXcel Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was €27.62 Mil.

BioXcel Therapeutics's quarterly Beginning Cash Position declined from Sep. 2024 (€50.70 Mil) to Dec. 2024 (€38.57 Mil) and declined from Dec. 2024 (€38.57 Mil) to Mar. 2025 (€27.62 Mil).

BioXcel Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€219.92 Mil) to Dec. 2023 (€177.65 Mil) and declined from Dec. 2023 (€177.65 Mil) to Dec. 2024 (€62.29 Mil).


BioXcel Therapeutics Beginning Cash Position Historical Data

The historical data trend for BioXcel Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Beginning Cash Position Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 26.66 188.61 219.92 177.65 62.29

BioXcel Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.00 68.88 50.70 38.57 27.62

BioXcel Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


BioXcel Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics Headlines

No Headlines